Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -97.60% is 41% above its 5-year average of -165.76%, around the middle of its 5-year range (-310.62%–-0.40%).
64.42% above its 12-month average of -274.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -33.85%.
RETURN ON ASSETS (ROA)
-97.60%
RETURN ON ASSETS (ROA) AVG TTM
-274.34%
RETURN ON ASSETS (ROA) AVG 3Y
-160.93%
RETURN ON ASSETS (ROA) AVG 5Y
-165.76%
RETURN ON ASSETS (ROA) AVG 10Y
-101.10%
RETURN ON ASSETS (ROA) AVG 15Y
-121.72%
RETURN ON ASSETS (ROA) AVG 20Y
-108.06%
CURRENT VS TTM AVG
+64.42%
CURRENT VS 3Y AVG
+39.35%
CURRENT VS 5Y AVG
+41.12%
CURRENT VS 10Y AVG
+3.46%
CURRENT VS 15Y AVG
+19.81%
CURRENT VS 20Y AVG
+9.68%
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-291.18%
vs the sector median at left
Enveric Biosciences, Inc.
Market Cap
$6.76M
Return on Assets (ROA)
-97.60%
TTM Avg
-274.34%
3Y Avg
-160.93%
5Y Avg
-165.76%
Market Cap
$6.74M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
Market Cap
$6.72M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
Market Cap
$6.88M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$7.03M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
-33.03%
Market Cap
$6.44M
Return on Assets (ROA)
-426.88%
TTM Avg
-139.62%
3Y Avg
-270.47%
5Y Avg
-207.15%
Market Cap
$6.34M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$6.10M
Return on Assets (ROA)
-99.97%
TTM Avg
-120.54%
3Y Avg
-89.96%
5Y Avg
-79.52%
Market Cap
$6.10M
Return on Assets (ROA)
-81.62%
TTM Avg
-81.33%
3Y Avg
-106.24%
5Y Avg
-102.80%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | $6.76M | -97.60% | -274.34% | -160.93% | -165.76% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -50.98% | -191.11% | -206.10% | -240.87% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -71.23% | -61.08% | -51.04% | -61.11% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -283.63% | -124.17% | -74.25% | -35.74% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | -206.32% | -53.14% | -33.03% | -33.03% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -426.88% | -139.62% | -270.47% | -207.15% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -55.85% | -69.75% | -63.38% | -59.39% |
| Femasys Inc. (FEMY)vs › | $6.10M | -99.97% | -120.54% | -89.96% | -79.52% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -81.62% | -81.33% | -106.24% | -102.80% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 83.82% | -0.56% | -31.49% | -28.41% |
ROA
-97.6%
ROE
-108.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -238.06% |
| 2024-12-31 | -310.62% |
| 2023-12-31 | -0.40% |
| 2022-12-31 | -94.64% |
| 2021-12-31 | -183.30% |
| 2020-12-31 | -167.56% |
| 2019-12-31 | -22.41% |
| 2018-12-31 | -57.01% |
| 2017-12-31 | -17.39% |
| 2016-12-31 | -7.04% |
| 2015-12-31 | -13.67% |
| 2014-12-31 | -661.63% |
| 2013-12-31 | -3.60% |
| 2012-12-31 | -439.66% |
| 2011-12-31 | -148.69% |
| 2010-12-31 | -3502.75% |
| 2009-12-31 | -3266.96% |
| 2008-12-31 | -206.15% |
| 2007-12-31 | 50.30% |
| 2006-12-31 | -76.07% |
| 2005-12-31 | -9.09% |
| 2004-12-31 | -10.76% |
| 2003-12-31 | -41.11% |
| 2002-12-31 | 1.05% |
| 2001-12-31 | -13.70% |
| 2000-12-31 | 15.55% |
| 1999-12-31 | 16.75% |
| 1998-12-31 | -648.28% |
| 1997-12-31 | -149.12% |
| 1996-12-31 | -613.23% |
